Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

× No keyword cloud information.

25 in total

1. Alzheimer's disease clinical trials: changing the paradigm.

Authors: Jeffrey L Cummings
Journal: Curr Psychiatry Rep Date: 2011-12 Impact factor: 5.285

2. Role of RanBP9 on amyloidogenic processing of APP and synaptic protein levels in the mouse brain.

Authors: Madepalli K Lakshmana; Crystal D Hayes; Steven P Bennett; Elisabetta Bianchi; Konda M Reddy; Edward H Koo; David E Kang
Journal: FASEB J Date: 2012-01-31 Impact factor: 5.191

3. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors: Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal: Neurobiol Aging Date: 2012-04-13 Impact factor: 4.673

Review 4. Cellular mechanisms of γ-secretase substrate selection, processing and toxicity.

Authors: Gael Barthet; Anastasios Georgakopoulos; Nikolaos K Robakis
Journal: Prog Neurobiol Date: 2012-05-20 Impact factor: 11.685

Review 5. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors: Daniela Puzzo; Ottavio Arancio
Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472

6. Possible directions for the discovery of new antidepressant treatments.

Authors: Simon N Young
Journal: J Psychiatry Neurosci Date: 2011-01 Impact factor: 6.186

7. L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged APP/PS1 Mouse Model of Alzheimer's Disease.

Authors: Yu Zhang; Long-Jian Huang; Si Shi; Shao-Feng Xu; Xiao-Liang Wang; Ying Peng
Journal: CNS Neurosci Ther Date: 2016-07-20 Impact factor: 5.243

What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?